AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference

Core Insights - AtriCure, Inc. is a leading innovator in surgical treatments for atrial fibrillation (Afib) and related conditions, participating in the J.P. Morgan 44th Annual Healthcare Conference [1][2] Company Overview - AtriCure provides innovative technologies for the treatment of Afib, which affects over 59 million people globally [3] - The Isolator® Synergy™ Ablation System is the first FDA-approved device for treating persistent Afib [3] - AtriCure's AtriClip® Left Atrial Appendage Exclusion System is the most widely sold device for left atrial appendage management worldwide [3] - The Hybrid AF™ Therapy offers a minimally invasive solution for long-standing persistent Afib patients [3] - AtriCure's cryoICE cryoSPHERE® and cryoXT® probes are designed for temporary ablation of peripheral nerves to alleviate pain in various medical procedures [3]